Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy
about
KASL clinical practice guidelines: management of chronic hepatitis BManagement of patients with hepatitis B who require immunosuppressive therapyOccult hepatitis B virus infectionPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyCurrent and future antiviral drug therapies of hepatitis B chronic infectionHepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy.Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.Hepatitis B reactivation and rituximab in the oncology practice.A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic ChemotherapySystematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy.Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies.Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.Treatment of special populations with chronic hepatitis B infection.Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.A drug safety evaluation of rituximab and risk of hepatitis B.Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Management of HBV infection during immunosuppressive treatmentA prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor.Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
P2860
Q26752475-5F7E6576-7E21-4987-BBB9-038F11481D16Q26853490-406ADF2C-3841-413A-98B1-E9FE66C4138AQ27004224-FE372CE6-20F4-499A-89B5-E869D86D7AA5Q28070090-549D087D-3F44-497F-B7FA-4E74BEAC0282Q28084820-15AC062B-265A-4CFB-9AFA-CD3423221A18Q33564294-B3C6EFCD-CB9F-4DA8-B876-BF76775F80E0Q34404991-840BD66A-59C8-4C95-B11D-027BA97FBBBEQ35073177-85961933-1E61-4D91-97D8-FE96DC79803FQ35375654-81142966-65F6-43E8-934F-615D12A7B281Q35583718-3C2254ED-ABB2-4260-89CE-74FB690D4B28Q35677319-0AD96810-2F57-41C4-8C8A-A0BC4B32862FQ36001152-31320E20-96F2-458E-A839-F1D0A14B3AE4Q36153966-CD2CAD90-31E7-48AD-B216-9417A7F3F101Q36220459-9FD8352E-9A92-4D0C-9751-8A910D6D33F8Q36245362-CCFE38D8-BC38-4550-AA80-9B068EDE3E1CQ36364001-86DF75F4-20F7-4E3E-9682-F5672CC16A7EQ36597776-BC6E9C0B-0FAC-483E-91AD-83ABF110A3EBQ36752181-30324004-D1FF-48F0-9063-911D21E45B98Q36957087-C3790C99-F631-4886-AB6D-2A82FBD57368Q37001173-135691D6-3AF6-4563-83C9-BF3C457427C9Q37065113-61C046BE-1270-4C19-B640-B29906194476Q37124256-05EF13D6-B20D-49DA-8357-422BA89F3B97Q37516930-F35E41A5-ABD1-4FBE-A0D9-FA9ACDBDFF0DQ37764963-96AA0CF2-ADA0-4CA5-8B19-D09FBE15FEF6Q37862588-290E3422-9AEC-469F-9403-DDC54F706884Q37886158-53BFCE6C-67F5-48B4-AA71-3E996DF12CE1Q37912229-4B03A8F0-8EFF-48E6-8802-67AF87FB398AQ37942651-4206FEC3-DAB8-4ED5-AA08-2B98B61E00EEQ37978202-AF7B564B-669D-4F44-A379-E9D94EE41143Q38211373-6909B662-2AF7-45AE-840F-D954803EC19DQ38218566-13E8138E-6B0E-4C31-B472-537219E45DF6Q38253568-B8A98FB5-E367-4635-9CBC-8E913D6F6958Q38613285-25863116-B146-4A74-B537-4EF62FF9EC55Q38665203-D4FB3525-D9D2-4DD0-AAFB-A94DEECADC1AQ40285910-231EF17F-B9D5-4EB9-9ED9-3C24BECD75ABQ40691267-853C21E7-BED1-4220-A31E-857E91B4E765Q40870495-8EDB69B3-4FEC-42FB-A9A4-038A1286A749Q41859437-1E6457A1-6E18-4C99-823A-59BE702433CAQ41990580-D442080E-17C1-4C09-9D18-1D9314186DE2Q42153911-FA0189BF-27F7-4647-9BB7-ACE3D40826DA
P2860
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@ast
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@en
type
label
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@ast
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@en
prefLabel
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@ast
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@en
P2093
P2860
P356
P1433
P1476
Hepatitis B reactivation after ...... tion of cytotoxic chemotherapy
@en
P2093
B C Y Wong
W W W Cheung
P2860
P304
P356
10.1136/GUT.2005.070763
P407
P577
2005-07-06T00:00:00Z